RSLSのチャート
RSLSの企業情報
| symbol | RSLS |
|---|---|
| 会社名 | ReShape Lifesciences Inc （エンテロメディックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Electromedical_Electrotherapeutic Apparatus |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 エンテロメディックス（EnteroMedics Inc.）は開発段階の医療機器会社であり、肥満、代謝性疾患及びその他消化器官疾患を治療するための神経遮断技術を応用するデバイスの設計・開発に集中している。同社の神経遮断技術は｢VBLOC｣療法として知られ、断続的に迷走神経をブロックするために設計された。同社の初期製品は「Maestro System」である。「Maestro System」は｢VBLOC｣療法を使用し、代謝調節制御に影響を与え、胃の膨張を制限し、食事間の飢餓感覚を制御し、胃収縮の頻度及び強度を低減し、早期で、長期の満腹感をもたらす。平成23年12月31日現在、無作為化で二重盲式の並行群間多施設臨床比較試験(充電試験)における同社の登録・注入は10カ所の施設で233人の患者によって完成されている。 エンテロメディックスは米国の医療機器開発会社。肥満、代謝性疾患、消化器疾患を対象に独自の神経遮断技術を使用する装置を開発。神経遮断技術はVBLOC療法として知られており、主な製品には減量治療法の「マエストロ・リチャ―ジャブル・システム」がある。欧州の認証マ―クを取得し、米国はじめ、オ―ストラリア、欧州経済地域、その他の国々で製品を販売。 ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. reshapecare™ is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. |
| 本社所在地 | 1001 Calle Amanecer San Clemente CA 92673 USA |
| 代表者氏名 | Dan W. Gladney ダンW・グラドニー |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 949-429-6680 |
| 設立年月日 | 37591 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 83人 |
| url | www.enteromedics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/rsls |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -36.88579 |
| 終値（lastsale） | 0.0349 |
| 時価総額（marketcap） | 2913194.7172 |
| 時価総額 | 時価総額（百万ドル） 2.37897 |
| 売上高 | 売上高（百万ドル） 2.75742 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 0.51678 |
| 当期純利益 | 当期純利益（百万ドル） -72.23706 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Reshape Lifesciences Inc revenues increased from $133K to $1.6M. Net loss applicable to common stockholders increased from $14.2M to $50.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling general and administrative increase of 76% to $15.3M (expense). |
RSLSのテクニカル分析
RSLSのニュース
ReShape Lifesciences (RSLS) Investor Presentation - Slideshow (NASDAQ:RSLS) 2023/05/01 10:53:27 Seeking Alpha
The following slide deck was published by ReShape Lifesciences Inc.
ReShape Lifesciences Inc. (RSLS) Q4 2022 Earnings Call Transcript 2023/04/29 17:12:02 Seeking Alpha
ReShape Lifesciences Inc. (NASDAQ:NASDAQ:RSLS) Q4 2022 Earnings Conference Call April 25, 2023 4:30 PM ETCompany ParticipantsMichael Miller - Investor RelationsPaul Hickey - President &…
ReShape Lifesciences reports FY results 2023/04/25 20:54:28 Seeking Alpha
ReShape Lifesciences press release (RSLS): FY Revenue of $11.24M (-17.9% Y/Y) misses by $2.24M.Net loss of $46.21M
ReShape Lifesciences Reports Year Ended December 31, 2022 Financial Results and Provides Corporate Update 2023/04/25 20:05:00 Wallstreet:Online
Continued Sequential Quarterly Growth in the U.S. With Q4 Revenues of $2.7 Million Improved Operational Effectiveness With Second Half 2022 Operating Expenses Down 27.9% Compared to the First Half of 2022, A $5.1 Million Reduction Executing A Plan For Profitability With A Balance Sheet Bolstered By Approximately $16.0 Million Raised Over the Last 12 Months Conference Call to be Held at
ReShape Lifesciences stock drops after pricing $2.5M equity offering (NASDAQ:RSLS) 2023/04/20 13:35:28 Seeking Alpha
ReShape Lifesciences (RSLS) shares dipped 9% on Thursday after the health solutions company priced an offering to raise $2.5M in gross proceeds.The firm entered into a securities…
77 Biggest Movers From Yesterday 2022/06/01 09:02:22 Benzinga
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD ) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners. JanOne Inc. (NASDAQ: JAN ) gained 66.5% to close at $3.73 after the company announced it sold GeoTraq to SPYR Technologies in a $13.5 million transaction. Mullen Automotive, Inc. (NASDAQ: MULN ) jumped 44.9% to settle at $1.40 after the company announced results of its solid-state polymer battery testing with the Battery Innovation Center in Indiana. Studio City International Holdings Limited (NASDAQ: MSC ) gained 43.3% to close at $3.21. CatchMark Timber Trust, Inc. (NYSE: CTT ) shares climbed 42.1% to close at $11.79 after the company and PotlatchDeltic announced they have entered into a definitive agreement to combine in an all-stock transaction. Xcel Brands, Inc. (NASDAQ: XELB ) gained 36.7% to settle at $1.49 after the company announced WHP will purchase a controlling 70% interest in fashion brand Isaac Mizrahi.
Earnings Scheduled For May 23, 2022 2022/05/23 08:51:37 Benzinga
Companies Reporting Before The Bell • Star Equity Hldgs (NASDAQ: STRR ) is expected to report quarterly loss at $0.15 per share on revenue of $25.45 million. • China Automotive Systems (NASDAQ: CAAS ) is estimated to report quarterly earnings at $0.07 per share on revenue of $126.27 million. • Niu Technologies (NASDAQ: NIU ) is likely to report earnings for its first quarter. • XPeng (NYSE: XPEV ) is likely to report quarterly loss at $0.28 per share on revenue of $1.09 billion. • Reshape Lifesciences (NASDAQ: RSLS ) is expected to report quarterly loss at $0.17 per share on revenue of $3.14 million. • Heliogen (NYSE: HLGN ) is projected to report quarterly loss at $0.06 per share on revenue of $5.24 million. • So-Young Intl (NASDAQ: SY ) is likely to report earnings for its first quarter. • QIWI (NASDAQ: QIWI ) is projected to report earnings for its first quarter. • Sonida Senior Living (NYSE: SNDA ) is projected to report quarterly loss at $4.84 per share on revenue … Full story available on Benzinga.
ReShape Lifesciences to Participate in Investor Conferences in March 2022/03/09 13:30:00 GlobeNewswire
SAN CLEMENTE, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced participation in the following investor conferences in March:
ReShape Lifesciences Inc. Shares Close in on 52-Week Low - Market Mover 2022/01/09 19:07:52 Kwhen Finance
ReShape Lifesciences Inc. (RSLS) shares closed today at 0.7% above its 52 week low of $1.53, giving the company a market cap of $27M. The stock is currently down 6.1% year-to-date, down 64.8% over the past 12 months, and down 99.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 63.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 77.2% The company's stock price performance over the past 12 months lags the peer average by 595.1%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Bariatric Surgery Devices Market 2021 Key Country Analysis: Ethicon, Medtronic, Intuitive Surgical, Apollo Endo surgery, ReShape Lifesciences 2021/12/18 08:48:08 OpenPR
The Bariatric Surgery Devices Market research report focuses on consolidations and acquisitions, extensions, examination of central participants, the foundation date of organization regions served, fabricating base, and income of vital participants. Moreover, the report also studies breakdown by product and
ReShape Lifesciences to Participate in Investor Conferences in March 2022/03/09 13:30:00 GlobeNewswire
SAN CLEMENTE, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced participation in the following investor conferences in March:
ReShape Lifesciences Inc. Shares Close in on 52-Week Low - Market Mover 2022/01/09 19:07:52 Kwhen Finance
ReShape Lifesciences Inc. (RSLS) shares closed today at 0.7% above its 52 week low of $1.53, giving the company a market cap of $27M. The stock is currently down 6.1% year-to-date, down 64.8% over the past 12 months, and down 99.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 63.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 77.2% The company's stock price performance over the past 12 months lags the peer average by 595.1%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Bariatric Surgery Devices Market 2021 Key Country Analysis: Ethicon, Medtronic, Intuitive Surgical, Apollo Endo surgery, ReShape Lifesciences 2021/12/18 08:48:08 OpenPR
The Bariatric Surgery Devices Market research report focuses on consolidations and acquisitions, extensions, examination of central participants, the foundation date of organization regions served, fabricating base, and income of vital participants. Moreover, the report also studies breakdown by product and
After A 3.47% Jump In The Last Week, Does ReShape Lifesciences Inc. (NASDAQ: RSLS) Still Make Sense To Buy? 2021/12/16 12:00:00 Marketing Sentinel
During the last session, ReShape Lifesciences Inc. (NASDAQ:RSLS)s traded shares were 1.16 million, with the beta value of the company hitting -1.09. At the end of the trading day, the stocks price was $2.09, reflecting an intraday gain of 5.03% or $0.1. The 52-week high for the RSLS share is $32.31, that puts it down After A 3.47% Jump In The Last Week, Does ReShape Lifesciences Inc. (NASDAQ: RSLS) Still Make Sense To Buy? Read More »
State Street Corp Takes Position in ReShape Lifesciences Inc. (OTCMKTS:RSLS) 2021/12/06 09:14:46 Transcript Daily
State Street Corp purchased a new position in ReShape Lifesciences Inc. (OTCMKTS:RSLS) in the second quarter, HoldingsChannel reports. The fund purchased 109,999 shares of the medical device companys stock, valued at approximately $550,000. Other hedge funds also recently added to or reduced their stakes in the company. Alpine Global Management LLC bought a new position []